The 2026 annual meeting of the National Lipid Association (NLA) is quickly approaching. From June 11 through June 14, 2026, in Chicago, Illinois, the 2026 NLA Scientific Sessions meeting is set to take place. The meeting is four days of networking opportunities, educational sessions, and hands-on learning experiences for health care professionals.

Today, we are taking a look ahead at key sessions currently scheduled for the 2026 NLA Scientific Sessions that attendees won’t want to miss. Times and dates are current as of May 7, 2026. NLA states that scheduling may be adjusted based on funding approval. For a complete look at the schedule, visit the official website to view the full agenda.

Thursday, June 11
  • 2026 Opening Session: “Lower for Longer”: Advancing Lipid Management in the Era of Evolving Evidence and 2026 Guideline Updates
    • 4:00 PM – 6:00 PM
    • Description: The opening session of the 2026 NLA Scientific Sessions features a look at the latest clinical trial findings and guideline updates. Real-world case challenges will be presented, and integrated audience polling will test attendees’ knowledge on topics including risk assessment, LDL-C and Lp(a) management, therapy selection, and treatment escalation.
Friday, June 12
  • Session II: From Genetic Discovery to Clinical Action
    • 9:00 AM – 10:30 AM
    • Description: This sessions features discussions on CRISPR-based gene editing, cascade screening in familial hypercholesterolemia, and the future of therapies driven by genetic discovery.
  • Session III: Later Breakers
    • 1:20 PM – 1:50 PM
    • Description: No details provided.
  • Session IV: Severe Hypertriglyceridemia: A Comprehensive Exploration of Uncommon Causes and Emerging Insights
    • 2:20 PM – 3:50 PM
    • Description: This sessions features discussions on lipodystrophy as a cause of severe hypertriglyceridemia, GPIHBP1 autoantibody syndrome, and persistent chylomicronemia.
  • Session V: NLA/EAS Joint Session – Primary Prevention of ASCVD
    • 4:20 PM – 6:05 PM
    • Description: This joint session between the National Lipid Association and the European Atherosclerosis Society will discuss updated guidelines, improving implementation, combination drug therapy, and more.
Saturday, June 13
  • Session VI: Rewriting the Rules for Primary Prevention: New Outcomes from Intensive LDL-C Reduction in High-Risk Patients
    • 9:00 AM – 10:30 AM
    • Description: This session features discussion on the clinical trials FOURIER, ODYSSEY, FOURIER OLE, and VESALIUS-CV.
  • Session VII: Abstract Award Winners
    • 11:00 AM – 12:30 PM
    • Description: This session features the following abstracts: Early Detection of Familial Hypercholesterolemia Through Point of Care Testing in 2-Year-Olds; Pooled Efficacy and Safety of Enlicitide, an Oral PCSK9 Inhibitor, Across Two Phase 3 Trials: CORALreef Lipids and CORALreef HeFH; Accelerating Lipoprotein(a) Testing in Community Health Centers Through Quality Improvement and Education; GLP-1 Receptor Agonists Rarely Cause Acute Pancreatitis but Induce Noninflammatory Acinar Hypertrophy, Pancreatic Enlargement and Mild Lipase Leak.
  • Session VIII: Young Investigator Award Winners
    • 1:30 PM – 2:35 PM
    • Description: This session showcases the top five winners of the young investigator awards. Third place: Treatment-Adjusted Phenotyping and Ascertainment Bias Correction Enable Accurate Familial Hypercholesterolemia Diagnosis: The TUDOR Algorithm; Second place: Opportunistic cardiometabolic risk detection in young blood donors; First place: Opportunistic cardiometabolic risk detection in young blood donors.
  • Session IX: Lipid Scholarship Program Case Discussions
    • 2:50 PM – 4:00 PM
    • Description: No details provided.
  • Session X: Managing the Child’s Trajectory: Intervening on Early Cardiometabolic Risk
    • 4:15 PM – 5:45 PM
    • Description: This session is set to discuss mitigating insulin resistance in young patients, pre-atherosclerotic imaging in pediatrics, and a discussion on overall family health.
Sunday, June 14
  • Session XI: Deciphering Women’s Risk: New Perspectives on Lipids, Pre-eclampsia, and Navigating HRT in Cardiometabolic Health
    • 9:00 AM – 10:30 AM
    • Description: This session features discussions on the role of lipids in pre-eclampsia, team-based care for women with CVD from preconception through postpartum, and the risk-benefit profile of HRT after the FDA policy shift.
  • Session XII: Inflammation: The GI, Metabolic, and Renal Link
    • 10:45 AM – 12:15 PM
    • Description: In this session, the role of non-invasive imaging in assessing MASLD-related inflammation and fibrosis, a strategy for attenuating inflammation and reducing cardiorenal risk, and lipoprotein(a) are set to be discussed.

Sign up for alerts and stay informed on the latest clinical guidelines and guideline updates.